CFAS  is a member of the newly formed European Prevention of Alzheimer’s Disease Consortium (EPAD) which launched in Paris on January 15th, 2015.  The start of a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.

EPAD is a collaborative research initiative to improve the chances of successfully preventing Alzheimer’s dementia and to better understand  early aspects of Alzheimer’s disease before dementia develops.  It is a five year programme which is part of the Innovative Medicines Initiative, a joint undertaking between  the European Union and the European Federation of Pharmaceutical industries and Associations, EFPIA.  It will establish a European-wide register of 24,000 participants of which 1,500 will be invited to participate in a trail to test new treatments for prevention of Alzheimer’s dementia. 

Further details can be found at http://www.synapse-managers.com/epad/